Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 3Neuroectodermal Tumors, Primitive, Peripheral 2Leukemia, Myeloid, Acute 2Carcinoma, Renal Cell 2Wilms Tumor 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Kidney Neoplasms 1Hepatoblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

Temozolomide 3Peripheral Blood Stem Cell Transplantation 3talazoparib 2Filgrastim 2lenvatinib 1irinotecan sucrosofate 1holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 1etoposide phosphate 1efineptakin alfa 1Radiotherapy 1Radiosurgery 1Nivolumab 1Microarray Analysis 1Melphalan 1Ipilimumab 1Immunohistochemistry 1Ifosfamide 1HhAntag691 1Everolimus 1Dasatinib 1Cyclophosphamide 1Carboplatin 1CTLA-4 Antigen 1Blotting, Western 1Amifostine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroectodermal Tumors, Primitive, Peripheral × talazoparib × Clear all
NCT04901702 2026-05-19

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
90 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT02116777 2021-03-26

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

National Cancer Institute (NCI)

Phase 1/2 Completed
40 enrolled 32 charts
CNS

Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡